Indian Journal of Endocrinology and Metabolism最新文献

{"title":"Efficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis.","authors":"Sweekruti Jena, Deep Dutta, Aniruddha Mukherjee, Ameya Joshi, A B M Kamrul-Hasan, Saptarshi Bhattacharya","doi":"10.4103/ijem.ijem_1037_25","DOIUrl":"10.4103/ijem.ijem_1037_25","url":null,"abstract":"<p><p>Antipsychotic medication-induced weight gain (AIWG) is a difficult-to-manage condition. Semaglutide is a widely used weight-lowering agent, but its role in AIWG has been evaluated in only few studies. This SRM evaluated if semaglutide can be effectively and safely used for AIWG in schizophrenia, bipolar disorder, and other psychiatric diseases. Electronic databases were searched for articles evaluating the use of semaglutide for managing AIWG. The primary outcome was reduction in body weight. Secondary outcomes were changes in body mass index (BMI), waist circumference (WC), HBA1c, metabolic parameters, and adverse events. Data from nine studies (44,233 participants; 4.21% diabetes; 94.79% euglycemia) which fulfilled all criteria were analysed. Semaglutide for AIWG was associated with a significant reduction in weight [mean difference (MD) -7.37 kg (95% confidence interval (CI): -12.39, -2.35); <i>P</i> < 0.001; I² = 99%], BMI [MD -2.76 kg/m² (95% CI: -4.15, -1.37); <i>P</i> < 0.001; I² = 98%], WC [MD -5.12 cm (95% CI: -7.21, -3.03); <i>P</i> < 0.001; I² = 76%], HbA1c [MD -0.35% (95% CI: -0.47, -0.24); <i>P</i> < 0.001; I² = 91%] and higher >5% weight loss [OR 2.25 (95% CI: 2.14, 2.36); <i>P</i> < 0.001; I² = 0%]. The occurrence of nausea, diarrhoea, and injection site reactions was similar. Vomiting was significantly higher in semaglutide users. The occurrence of psychiatric adverse events was lower in semaglutide users but not significant [OR 0.59 (95% CI: 0.33-1.07); <i>P</i> = 0.08; I² = 0%]. Semaglutide has good efficacy data with regard to quantum of weight loss with good safety for managing AIWG.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 2","pages":"119-128"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Indian Obesity Paradox- Low in Muscle, High in Fat.","authors":"Sri V Madhu, Nishant Raizada","doi":"10.4103/ijem.ijem_245_26","DOIUrl":"10.4103/ijem.ijem_245_26","url":null,"abstract":"","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 2","pages":"115-118"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between DPP-4 Gene Expression and T-Cell Subset Marker Genes in Chronic Liver Disease Patients in Eastern India: An Observational Study.","authors":"Bikramjit Barkondaj, Partha Chakrabarti, Satinath Mukhopadhyay, Dipyaman Ganguly, Nilanjan Sengupta, Chandan Chatterjee, Avijit Hazra, Chiranjit Bose","doi":"10.4103/ijem.ijem_397_25","DOIUrl":"10.4103/ijem.ijem_397_25","url":null,"abstract":"<p><strong>Introduction: </strong>The role of dipeptidyl peptidase-4 (DPP-4/CD26) in chronic liver disease (CLD) remains incompletely understood, particularly its interaction with immune cells. This study investigates the association between DPP-4 gene expression and T-cell subset marker genes in CLD patients, aiming to elucidate potential immunological mechanisms underlying disease progression.</p><p><strong>Methods: </strong>A total of 130 individuals were enrolled across four groups: non-alcoholic fatty liver disease (NAFLD; <i>n</i> = 46), non-alcoholic cirrhosis (NAC; <i>n</i> = 23), alcoholic cirrhosis (ALC; <i>n</i> = 21), and healthy controls (<i>n</i> = 40). Peripheral blood samples were analysed for biochemical parameters and DPP-4 activity. Gene expression profiling was conducted in peripheral blood mononuclear cells to assess DPP-4 and T-cell marker genes (TBX21, RORC, GATA3, FOXP3, and CD3D).</p><p><strong>Results: </strong>DPP-4 expression was elevated in all CLD subgroups, reaching statistical significance in NAFLD (<i>P</i> = 0.0142). The Th1 marker TBX21 showed increased expression, significantly in NAC (<i>P</i> = 0.0091), and demonstrated a strong correlation with DPP-4 in non-alcoholic CLD. The Th17 marker RORC was significantly elevated in NAFLD (<i>P</i> = 0.016), whereas the Th2 marker GATA3 and the Treg marker FOXP3 were significantly reduced (<i>P</i> = 0.0049 and <i>P</i> = 0.0028, respectively), with FOXP3 showing a negative correlation with DPP-4 (<i>r</i> = 0.588). CD3D expression correlated with DPP-4 in ALC patients.</p><p><strong>Conclusion: </strong>These findings suggest disrupted regulatory coordination rather than uniform Treg suppression across CLD subgroups. NAFLD exhibited partial Th17 polarisation, whereas NAC may reflect Th17 exhaustion. DPP-4 appears to be associated with Th1 responses and may contribute to liver injury in NAC.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 2","pages":"135-141"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial.","authors":"Vishal Agarwal, Sambit Das, Arun K Choudhury, Dayanidhi Meher, Devadarshini Sahoo, Sandeep K Sahu, Subhadra Priyadarshini, Sonam J Agarwal, Binod Prusty, Bijay K Das, Amogh S Chappalagavi, Sheenam Gupta","doi":"10.4103/ijem.ijem_635_25","DOIUrl":"10.4103/ijem.ijem_635_25","url":null,"abstract":"<p><strong>Introduction: </strong>Insulin resistance plays the central role in the pathophysiology of polycystic ovary syndrome (PCOS). While metformin is widely used, its metabolic and androgen-lowering benefits are modest and often limited by tolerability, highlighting the need to evaluate newer therapeutic agents targeting insulin resistance in PCOS. Dapagliflozin complements metformin's effects through an insulin-independent mechanism of action and may be beneficial in improving metabolic outcomes in PCOS.</p><p><strong>Methods: </strong>Women diagnosed with PCOS based on Rotterdam criteria were randomly allocated to receive either dapagliflozin (10 mg daily) plus metformin (2000 mg/day) or metformin (2000 mg/day) alone, over a 12-week period.</p><p><strong>Results: </strong>At 12 weeks, there were no statistically significant differences between the dapagliflozin plus metformin group and the metformin alone group in improving insulin resistance or biochemical hyperandrogenism. While within-group changes were statistically significant, the differences between the two arms did not achieve statistical significance. Mild adverse effects, including urinary tract infections and vaginal irritation, were reported more in the dapagliflozin plus metformin group than the metformin alone group.</p><p><strong>Conclusion: </strong>In overweight and obese women with PCOS, the addition of dapagliflozin to metformin did not result in significant improvement in insulin resistance or hyperandrogenaemia over metformin alone and was associated with a higher rate of adverse effects. Larger and longer-term trials are needed to fully clarify their role in routine clinical care.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"71-78"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Profile and Response to Recombinant Growth Hormone in Girls with Turner Syndrome: Experience from a Tertiary Care Centre in North India.","authors":"Pamali M Nanda, Arti Yadav, Arun George, Sayan Banerjee, Anju Bala, Jaivinder Yadav, Rakesh Kumar, Inusha Panigrahi, Devi Dayal","doi":"10.4103/ijem.ijem_348_24","DOIUrl":"10.4103/ijem.ijem_348_24","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to describe the clinical presentation and response to recombinant growth hormone (rGH) in Indian girls with Turner syndrome (TS).</p><p><strong>Methods: </strong>This retrospective study included 33 girls with TS attending a tertiary care hospital in Northern India between 2004 and 2023. Data on clinical presentation, cytogenetics and follow-up were retrieved from clinic records. In addition, auxological data was analysed for girls who received rGH therapy.</p><p><strong>Results: </strong>The mean age at presentation was 9.8 ± 3.9 years (range 2-17.7 years). 57.6% had classical TS, whereas, 42.4% had variant TS karyotypes. The commonest presenting features were short stature (100%) and delayed puberty (27.3%). Autoimmune hypothyroidism and celiac disease were the commonest associated co-morbidities. Pubertal induction with estradiol was done in seven patients. Sixteen (48.5%) patients received rGH at a mean starting dose of 0.29 mg/kg/week. The mean age and bone age (BA) at rGH initiation were 10.0 ± 3.3 years and 8.3 ± 3.0 years, respectively. There were significant improvements in Turner's height standard deviation scores (SDS) (-0.7 to 0.19; <i>P</i> = 0.003), BA (8.3 ± 3.0 to 10.2 ± 2.9; <i>P</i> = 0.003) and predicted adult height (PAH) (142.2 cm to 147.4 cm; <i>P</i> < 0.001) over a median duration of rGH therapy of 16 months (IQR 6-51 months). There was a strong positive correlation between height gain and duration of rGH therapy (<i>r</i> = 0.967; <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>North Indian girls with TS demonstrate a good response to rGH with improvements in height SDS, PAH, and skeletal growth. The duration of rGH significantly impacts height gain; early initiation is therefore crucial for attaining near-normal final height.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"102-106"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Endocrine Manifestations in HIV-Infected Subjects on Anti-Retroviral Therapy (ART) Versus not on ART.","authors":"Satyaki Manna, Tapas C Das, Kaushik Pandit, Pradip Mukhopadhyay, Purushottam Chatterjee, Sujoy Ghosh","doi":"10.4103/ijem.ijem_425_25","DOIUrl":"10.4103/ijem.ijem_425_25","url":null,"abstract":"<p><strong>Introduction: </strong>Few studies have examined endocrine dysfunction associated with anti-retroviral therapy (ART) for human immunodeficiency virus (HIV) infection. The aim is to assess various endocrine changes, including vitamin D metabolism and glycaemic status, of subjects on ART versus not on ART (non-ART) and to assess the relationship with CD4 + T helper cell count.</p><p><strong>Methods: </strong>Ninety-three HIV-positive subjects were selected and underwent thyroid function tests (thyroid stimulating hormone and free thyroxine). Fasting plasma glucose, glycated haemoglobin, Cortisol, ACTH, total testosterone (male), follicle stimulating hormone, luteinising hormone, Prolactin, 25(OH) D, intact parathyroid hormone, calcium, phosphorus, albumin and magnesium levels, and CD4+ T-helper cell counts were performed in all subjects.</p><p><strong>Results: </strong>There was a positive correlation between vitamin D and CD4 count (<i>r</i> = 0.33, <i>P</i> = 0.043) and severe vitamin D deficiency (30% in ART vs. 6.00% in non-ART; <i>P</i> = 0.035). 37.50% of the ART group had secondary hyperparathyroidism, compared to 12.10% of the non-ART cohort (<i>P</i> = 0.014). The most common adrenal dysfunction was found to be primary adrenal insufficiency, followed by adrenal excess and secondary adrenal insufficiency (17.50%, 10.00% and 2.50% in ART vs. 15.00%, 12.00% and 6.00% in the non-ART group); male hypogonadism was seen in 22.70% of patients in the ART group versus 14% in the non-ART group (<i>P</i> = 0.064). The most common thyroid dysfunctions found in the ART cohort were secondary hypothyroidism (30%), subclinical hypothyroidism (10%), and primary hypothyroidism (2.50%).</p><p><strong>Conclusion: </strong>Our study showed endocrine dysfunction more common in patients who received ART than in those who did not. Severe vitamin D deficiency was also common in the ART group. Serum vitamin D levels were positively correlated with CD4+ T cell counts.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"96-101"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D Status and Calcium Homeostasis in Mother and Newborn Dyad: A Hospital Based Study from South Delhi.","authors":"Alankrita Goswami, Sangita Yadav, Sana S Khan, Aruna Nigam, Sana Alam","doi":"10.4103/ijem.ijem_799_25","DOIUrl":"10.4103/ijem.ijem_799_25","url":null,"abstract":"<p><strong>Introduction: </strong>Studies in the 2000s in India showed a high prevalence of vitamin D deficiency in apparently healthy pregnant women and their newborns. With awareness about sunshine exposure and vitamin D supplementation, vitamin D deficiency would have declined over the last two decades. We assessed current vitamin D status of maternal-newborn dyads at a teaching institute in Delhi.</p><p><strong>Methods: </strong>The study included 104 pregnant women (27.8 ± 4.2 yrs) and their singleton healthy term newborns (M: F = 63:41) delivered at HIMSR Delhi during years 2023-25. Cord-blood was drawn at delivery, and fasting maternal blood was drawn for serum total calcium, phosphate, alkaline phosphatase, 25(OH)D, and intact-PTH assessment. Serum 25(OH)D and PTH were measured by chemiluminescence assay.</p><p><strong>Results: </strong>The median (IQR) serum 25(OH)D of mothers and newborns was 11.8 (6.9-19.1) and 13.7 (7.9-24.7) ng/mL, respectively. Serum 25(OH) was <12 ng/mL in 51% of mothers and 44% of newborns. Maternal and cord-blood 25(OH)D correlated significantly (<i>r</i> = 0.945, <i>P</i> < 0.001). Maternal serum 25(OH)D correlated inversely with iPTH (<i>r</i> = -0.400, <i>P</i> < 0.01). Maternal and cord-blood iPTH showed no significant correlation. Serum calcium (9.1 ± 1.2 vs. 10.9 ± 1.1 mg/dL, <i>P</i> < 0.001) and phosphate (4.4 ± 0.9 vs. 6.2 ± 1.1 mg/dL, <i>P</i> < 0.001), were lower in mothers than newborns unlike alkaline phosphatase (200 ± 77 vs. 138 ± 39 IU/L, <i>P</i> < 0.001) which was higher in mothers. Serum phosphate was significantly lower in male than female newborns, while 25(OH)D and total calcium were comparable.</p><p><strong>Conclusion: </strong>A high prevalence of vitamin D deficiency in mothers and newborns was observed, despite two decades of awareness. This emphasizes for more targeted and proactive public health initiatives to combat maternal and neonatal hypovitaminosis D.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"51-57"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Cortisol Responses to Spontaneous Hypoglycaemia Versus Adrenocorticotropic Hormone Stimulation: A Diagnostic Challenge for Hypothalamic-Pituitary-Adrenal Axis Assessment.","authors":"Pushpa Machineni, Asha Ranjan, Adlyne R Asirvatham, Shriraam Mahadevan","doi":"10.4103/ijem.ijem_925_25","DOIUrl":"10.4103/ijem.ijem_925_25","url":null,"abstract":"<p><strong>Introduction: </strong>The hypothalamic-pituitary-adrenal (HPA) axis is a critical regulator of cortisol secretion, assessed via dynamic tests such as the insulin tolerance test and adrenocorticotropic hormone (ACTH) stimulation test. Discordant cortisol responses in recurrent hypoglycaemia that is, blunted secretion during hypoglycaemia but preserved under ACTH stimulation, pose a diagnostic challenge in evaluating adrenal insufficiency (AI).</p><p><strong>Methods: </strong>A retrospective study was conducted in five patients (two females, three males) with spontaneous fasting hypoglycaemia (blood glucose <55 mg/dL). All patients had undergone critical sampling at the time of hypoglycaemia, including measurements of serum cortisol, insulin, C-peptide, urine ketone whereas ACTH-stimulated cortisol response was assessed using the long-acting porcine sequence ACTH (Acton Prolongatum^®).</p><p><strong>Results: </strong>All five patients [insulinoma: 2, insulin autoimmune syndrome: 2 (presumed in 1), presumed insulin-like growth factor 2 related hypoglycaemia: 1] with spontaneous fasting hypoglycaemia had suboptimal cortisol levels (range: 6.15-14 μg/dL) during hypoglycaemia but adequate cortisol response (>18 μg/dL) post-ACTH stimulation.</p><p><strong>Conclusion: </strong>Low cortisol levels during recurrent hypoglycaemia should be interpreted cautiously, and AI should be diagnosed only after a comprehensive evaluation. A normal ACTH stimulation test can rule out AI assertively in such scenario. Further studies are needed to clarify the mechanisms of this discordance.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"85-88"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Historical Account of Endocrinology in Ancient India.","authors":"Akhila Bhandarkar, Shinjan Patra","doi":"10.4103/ijem.ijem_381_25","DOIUrl":"10.4103/ijem.ijem_381_25","url":null,"abstract":"<p><p>Endocrinology is the study of tiny chemical messengers secreted from the various glands into the blood that regulate metabolism and a vast array of bodily functions. The earliest rudimentary observations and evolution of endocrinology were documented in the early 17^th and 18^th centuries. The prevalent procedure of castration led to the observation of the effect and the importance of male gonads. Earnest Sterling coined the term \"Hormone\" in 1905 and identified \"Secretin,\" the first substance recognized as a hormone in 1902. Starting from our ancient texts, the Charaka Samhita and Sushruta Samhita, and later on, to the magnum opus epics, the Ramayana and Mahabharata, there are many references to endocrinological diseases, their descriptions, and remedies. Our brief review aims to draw a similar analogy between these references and contemporary endocrinology practices.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"111-114"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine Society of India's National White Paper on Endocrine Disrupting Chemicals - A Call for Action.","authors":"Gagan Priya, Narendra Kotwal, Sri V Madhu, Shinjan Patra, Kaushik Pandit, Beatrice Anne, Mohan T Shenoy, Jayshree Swain, Sambit Das, Lakshmi N Kopalle, Lakshmi Nagendra, Saptarshi Bhattacharya, Shehla S Shaikh, Sunetra Mondal, Ganesh K Bhat, Ameya Joshi, Sanjay Kalra, Kaushik Biswas, Hari K V S Kumar, Sunil K Mishra, Deep Dutta, Nitin Kapoor, Sachin Mittal","doi":"10.4103/ijem.ijem_976_25","DOIUrl":"10.4103/ijem.ijem_976_25","url":null,"abstract":"<p><p>Endocrine disrupting chemicals (EDCs) are exogenous substances that interfere with hormonal pathways, leading to a broad spectrum of adverse health outcomes across the life course. This white paper by the Endocrine Society of India consolidates global and Indian evidence on EDC exposure, health effects, and regulatory challenges. Major classes of EDCs, including pesticides, industrial pollutants, plastic additives, and heavy metals, affect neurodevelopmental, reproductive, metabolic, musculoskeletal, thyroid and other outcomes, with implications extending to future generations through epigenetic and transgenerational effects. Indian data reveal widespread exposure through food, water, packaging material, and industrial waste, with studies linking EDCs to infertility, polycystic ovary syndrome, obesity and diabetes. Despite growing awareness, India lacks a comprehensive regulatory and surveillance framework for EDCs. This white paper outlines key gaps and provides actionable recommendations: strengthening systematic monitoring, harmonizing regulations, promoting research on emerging chemicals, fostering cross-sector and international collaboration, and empowering healthcare professionals and the public. Adoption of structured regulatory mechanisms modeled on global frameworks, combined with public education and institutional accountability, is essential to mitigate risk. Coordinated national efforts that bridge science, policy and community action are urgently needed to safeguard health and environment for future generations.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"30 1","pages":"4-19"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}